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Obesity is a strong risk factor for cardiovascular disease. It is defined by an unhealthy excess 
of white adipose tissue (WAT). Adipose derived weight gains and losses are linked to 
changes in two other independent cardiovascular risk factors: hypertension, and arterial 
stiffness. The aim of this thesis was to explore which specific WAT factors associate with 
hypertension and arterial stiffness.  
Subjects undergoing bariatric surgery were utilized as a model system for linking different 
WAT conditions with vascular outcomes. Phenotyping methods included anthropometric 
measurements, hyperinsulinemic euglycemic clamp, dual energy Xray absorptiometry 
assessment of WAT distribution and adipose tissue biopsies for RNA sequencing and in vitro 
assessments of adipocyte function and characteristics.  
Study I assessed the cross-sectional relationships between WAT factors in obese individuals 
(n = 120) and pulse wave velocity (PWV), a measure of arterial stiffness. After adjusting for 
relevant confounders, only visceral adipocyte volume was significantly (and positively) 
associated with PWV. Study II determined if weight loss resulted in long term reductions in 
PWV and if any WAT factors could predict improvement. The same individuals, except those 
on antihypertensive pharmacotherapy, were included (n = 82). Subjects were reassessed two 
years after bariatric surgery and attained a pronounced weight reduction and a significant 
reduction in PWV. After adjusting for confounders, subcutaneous adipocyte volume and 
WAT COL4A1 gene expression was found to predict improvements in PWV. Study III 
investigated which WAT factors associated with blood pressure improvements after weight 
loss. Here, only hypertensive subjects who underwent RNA sequencing (both at fasting and 
in hyperinsulinemic state, after a two-hour hyperinsulinemic euglycemic clamp) were 
included, ten who improved and eight who did not. WAT insulin sensitivity (defined as WAT 
insulin induced transcriptomics) was the only WAT factor that differed between the two 
groups, with both a larger response seen at baseline and a larger increase after weight loss 
observed in the improved group compared to the non-improved group. Finally, perturbed 
adipose tissue lipolysis is a hallmark of WAT in obesity, contributing to pathophysiological 
whole-body effects. However, the effects of obesity on atrial natriuretic peptide (ANP) 
stimulated lipolysis, have never been studied. In Study IV ANP stimulated lipolysis was 
impaired in vitro in obesity (n=87) but normalized after weight loss (n = 52). Furthermore, 
ANP stimulated lipolysis was attenuated in situ in overweight men (n = 9). Protein analysis 
found obese WAT to have a lower expression of NP receptor A which may explain the 
blunted response.  
In summary, studies in this thesis have contributed to the characterization of specific WAT 
factors that associate with circulatory system pathology and, for the first time, characterized 
the ANP stimulated lipolytic response in obesity.  
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1.1 OVERWEIGHT AND OBESITY 
Being overweight or obese is defined by having an excess fat accumulation for a given 
height. The most common categorization method is by body mass index (BMI), which is 
calculated by dividing a person’s weight in kilograms by their squared height in meters. 
Values above 25 are termed overweight, above 30 obese, above 35 severe obesity and above 
40 morbid obesity. The formula has pitfalls: muscle weighs more than fat, causing e.g., body 
builders to frequently have an unhealthy BMI which is not due to having excessive fat tissue.  
The direct cause of increasing body weight is an imbalance between energy intake and 
expenditure (Figure 1), which in turn may be due to a wide range of factors. This occurs 
despite that few desire to be overweight or obese, as both most modern-day beauty standards 
and health views support a lean body type.  
Our environment has become increasingly obesogenic. Labor used to be manual, forcing us 
to expend energy to earn a living. Food was generally unprocessed and relatively energy 
poor. Today, sedentary jobs dominate, while food is available anywhere, and anytime. It is 
often processed and rich in calories. When served in restaurants portion sizes often widely out 
scale public health recommendations [1], and it’s been shown that humans will consume 
500Kcal/day more given an ad libitum intake of an ultra-processed diet compared to an 
unprocessed one [2]. Obesity prevalence has doubled since 1980 [3], in Sweden it is now 
more common for adults to be overweight and obese compared to lean, [4] and increases in 
body weight can be seen across the entire population spectrum around the globe.  
This obesity epidemic has severe consequences far greater than any perceived cosmetic 
downsides, with deaths attributed to an excess fat accumulation estimated at 2.8 million per 
year [3]. Furthermore, it is at least partially responsible for 44% of the diabetes burden, 23% 
of ischemic heart disease and between 7-41% of different cancer incidences [3]. On average, 
if you are obese at age 40 your life expectancy will be reduced by roughly four years 
compared to that of a lean individual [5]. 
1.1.1 Metabolic syndrome 
Excess adipose tissue (especially when located around the midsection) is often associated 
with dyslipidemia, insulin resistance and hypertension. To prompt awareness and attention, 
clinicians and researchers coined the term metabolic syndrome; a constellation of risk factors 
commonly occurring together which greatly increase the risk of type 2 diabetes and 
cardiovascular disease (CVD). Specific inclusion criteria and cut off values have varied by 
different defining organizations, but harmonizing attempts have been made and measures 
now include increased waist circumference (population specific), reduced HDL-C 
(<1mmol/l), raised triglycerides (TG) (1.7 mmol/l), elevated blood pressure (130 systolic and 




Figure 1. Either a hypercaloric intake or lowering of energy expenditure will lead to 
increasing body weight. BMR: basal metabolic rate  
1.2 OBESITY TREATMENT 
Medical treatment of obesity is aimed at reducing and maintaining at least a 5-15% weight 
reduction, as this has proven to induce significant beneficial effects in obesity-related 
outcomes [7].  
1.2.1.1 Lifestyle treatment 
The cornerstone of obesity treatment is lifestyle changes, with reduction in caloric intake 
and/or an increase in physical exercise. While this strategy results in significant weight loss, 
the effect is often transient and difficult to maintain. This is demonstrated e.g., by the Look 
Ahead trial which over a 10-year follow-up showed a 6% body weight reduction in the 
intervention group vs a 3.5% in the control group. The trial was stopped after 10 years as 
there was no difference in cardiovascular events between the groups [8]. In line with this, the 
recent DIRECT trial found only 11% of the study population were able to maintain a 15kg 
weight loss at 24 months [9]. Despite the somewhat disappointing effects on body weight, it 
is clear that lifestyle interventions can prevent new onset cases of diabetes [10, 11].  
1.2.1.2 Pharmacotherapy treatment 
Pharmacological treatment is currently available in three different forms: orlistat a compound 
inhibiting intestinal lipases, leading to a 30% reduction in fat uptake; bupropion/naltrexone 
which reduces food craving (it is rarely prescribed as it can increase suicide and mood 
disorders); and liraglutide, an incretin analogue, which decreases appetite and food intake. Of 
these, liraglutide has shown the most promise with the highest proportion of users being able 
to achieve at least a 5% weight loss at 12 months [12]. In the US, the drug combination of 
phentermine (an appetite reducing drug) and topiramate, an anticonvulsant, is also registered 
and can achieve a 5% weight loss [12].  
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1.2.1.3 Bariatric surgery 
Bariatric surgery has been proven more effective compared to non-surgical treatment, in 
reducing body weight, with subjects losing on average an extra 26 kg [13]. It can also achieve 
diabetes and hypertension remission [13, 14] and lower mortality [15]. There are several 
different surgical techniques used today (Figure 2), with the most common ones obtaining 
comparable short- and long-term results [16, 17]. Today (2017), in Sweden, the most 
common surgical technique is the Roux-en-Y gastric bypass (RYGB) [18], where a small 
gastric pouch is connected straight to the jejunum, while the rest of the stomach, no longer 
connected to the esophagus, with the bypassed duodenum is anastomosed to the jejunum. 
Gastric sleeve is becoming almost as common. Here, a large part of the stomach is stapled 
off, leaving only about 10-20% of the original area, but there is no anatomical rearrangement. 
Other techniques include laparoscopic adjustable gastric banding, where a silicone band is 
placed in the upper part of the stomach and filled with saline, restricting access to the gastric 
pouch. It is less popular today, as the band can erode, lose effectiveness, and cause 
complications such as gastro-esophageal reflux disease. Finally there is the biliopancreatic 
diversion with duodenal switch, a much more challenging and anatomically altering 
procedure which, while considered the most effective treatment for severe obesity, is hardly 
used due to long term nutritional deficiencies and short term complications such as surgical 
leaks or obstruction [19]. In total about 5400 bariatric surgeries were performed in Sweden in 
2017 [18]. It’s believed that the weight loss effect comes not only from the restrictive effect 
of surgery, but also due to a functional and structural change of the gastrointestinal tract 
leading to alterations in many hormones, particularly incretins (e.g., glucagon-like peptide 1, 
gastric inhibitory polypeptide). These hormonal changes mainly affect the brain and induce 
satiety [20].  
1.3 ADIPOSE TISSUE 
Adipose tissue had long been viewed solely as a storage space for excess calories. Research 
during the last decades have discovered it to be a complex tissue engaged in cross talk with 
multiple other organ systems and playing a vital role in energy storage and whole-body 
metabolic homeostasis. Volume-wise it is comprised of 90% adipocytes: the cell type 
specialized in storing lipids in the shape of a droplet. Numerically adipocytes make up only 
about between 20-40% of cell content [21]. The remaining cells are fibroblasts, endothelial 
cells, adipocyte precursors and different types of immune cells such as macrophages, 





Figure 2. Bariatric surgery techniques. a | Roux-en-Y gastric bypass. b | Adjustable gastric 
band. c | Sleeve gastrectomy. d | Biliopancreatic diversion with duodenal switch. Figure 
adapted and reprinted with publishers’ permission from Nguyen, N.T. and J.E. Varela, 
Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol 
Hepatol, 2017. 14(3): p. 160-169. 
1.3.1 Brown adipose tissue 
Adipocytes can be subdivided based on function into white or brown adipocytes. Brown 
adipocytes are far outnumbered by white adipocytes. They generate heat through a specific 
protein, Uncoupling Protein 1 (UCP1), expressed in the mitochondria, white adipocytes lack 
this protein. Mitochondria store energy as a proton gradient, and as protons flow down their 
gradient across the mitochondrial membrane they pass through ATP synthase complex, 
creating ATP. In brown adipocytes there is an alternate route, through an uncoupling protein 
in the membrane, UCP1, thus the energy dissipates as non-shivering thermogenesis as 
opposed to creating ATP [22].  
Brown adipocytes cluster prominently in specific depots in the neck and scapular areas of 
young children, while adult humans only have smaller depots throughout the body. 
Interestingly, cold climate and some pharmacotherapies can induce more brown adipose 
tissue as well as making white adipose tissue (WAT) “beige” i.e., gaining characteristics of 
brown adipose tissue [23].  
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1.3.2 White adipose tissue 
White adipose tissue is the main storage site for lipids in the form TGs, which are fatty acid 
chains attached to a glycerol molecule. Depending on hormonal and neurological stimulation 
it can take up fatty acids from the bloodstream and increase its lipid storage, a process termed 
lipogenesis. Upon fasting or during times of starvation, lipids are hydrolyzed through an 
enzymatic process termed lipolysis, which provides free fatty acids and glycerol as fuel for 
other tissues. 
1.3.2.1 Lipolysis 
Lipid droplets are coated with proteins, such as perilipin-1 (PLIN), restricting access from 
hydrolyzing lipases. Structural changes are required to initiate increased lipolysis in 
adipocytes. Lipolysis is stimulated by catecholamines and natriuretic peptides and inhibited 
by insulin. Catecholamines and natriuretic peptides bind cell surface receptors, increasing 
intracytosolic concentrations of their respective second messengers (cAMP and cGMP) 
which in turn bind and activate protein kinase A and G (PKA, PKG). These protein kinases 
phosphorylate hormone-sensitive lipase (HSL), translocating it from the cytosol onto the lipid 
droplet. Here HSL interacts with PLIN. PLIN is also directly phosphorylated by PKA and 
PKG, releasing a regulatory component to instead interact and activate another lipase, 
adipose TG lipase (ATGL). ATGL, HSL and monoglyceride lipase catalyze the hydrolysis of 
TGs into fatty acids and glycerol which are then either oxidized for energy or released from 
adipocytes into the bloodstream for use by other organs and tissues. Insulin inhibits lipolysis 
in part by activating an enzyme, phosphodiesterase 3B, which degrades cAMP. 
1.3.2.2 Adipokines 
Adipose tissue is a hormonally active tissue. To date several hundred different hormones and 
cytokines, collectively named adipokines have been discovered. They can be secreted from 
one or several cell populations within adipose tissue, display a wide variety of effects and 
affect many different organs and tissues. Notable examples are TNF-α, a pro-inflammatory 
cytokine attracting leukocytes, inducing insulin resistance and able to stimulate the acute 
phase reactants in the liver. Adipose tissue TNF-α is believed to act mainly on adipose tissue 
in a autocrine or paracrine manner, inducing local and systemic insulin resistance in part by 
increasing basal lipolysis [24]. Adiponectin is exclusively produced in adipose tissue and has 
many beneficial effects, including increasing skeletal muscle oxidation of fatty acids and 
decreasing hepatic glucose production [25]. Its expression and serum concentration are 
inversely correlated with adipose tissue mass. Leptin [26] secretion instead rises with 
increasing adipose tissue mass and decreases appetite by acting on the hypothalamus.  
1.3.3 Adipose tissue depots and distribution 
WAT is distributed in different depots in the body. Most of it is located either 
subcutaneously, under the skin, or viscerally, around the internal organs. There are sexual 
predispositions as to where excess WAT is stored, with men on average having more visceral 
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and women more subcutaneous adipose tissue. Hormones likely play a part, as women after 
menopause become more male-like in their adipose tissue distribution [27]. Glucocorticoids 
also promote visceral fat accumulation [27].  
Excess visceral WAT seems to be more pernicious than subcutaneous WAT. Epidemiological 
data shows that a larger visceral adipose depot is associated with dyslipidemia and 
cardiovascular complications [28]. Two main explanations for this have been brought 
forward: visceral adipose tissue is found near and around the internal organs, and blood flow 
from the depot drains into the portal system directly onto the liver, and/or there are cell 
autonomous differences within the different depots [23]. Interestingly, differential gene 
signatures can be identified between visceral and subcutaneous adipocytes and differences are 
retained even after several passages in vitro [29]. Lastly, in mice transplanting subcutaneous 
adipose tissue into a visceral depot improves glucose homeostasis while the reverse has no 
effect [30].  
1.4 INSULIN 
Insulin is an anabolic hormone released from specialized cells, beta-cells, in the pancreas in 
response to increasing blood glucose levels. It has a variety of different effects in various 
target organs. Thus, in adipose tissue and skeletal muscle, insulin promotes glucose uptake 
and in skeletal muscle also glycogen synthesis. Furthermore, in adipose tissue, insulin 
promotes lipogenesis and inhibits lipolysis. In liver insulin also promotes glycogen synthesis 
and increases de novo lipogenesis while decreasing gluconeogenesis and glucose output.  
1.4.1 Insulin signaling 
Insulin is a peptide hormone (it cannot pass through cell membranes) that binds a specific cell 
surface insulin receptor. The insulin receptor is a transmembrane homodimer composed of 
alpha and beta subunits. Alpha subunits are extracellular and bind insulin. Upon binding, the 
receptor undergoes a structural change and the intracellular beta subunit, which has tyrosine 
kinase enzymatic activity, is autophosophorylated and subsequently phosphorylates a target 
protein known as insulin receptor substrate. This starts a signaling cascade targeting several 
proteins eventually leading to phosphorylation and activation of AKT, a serine/threonine 
kinase. AKT has over 100 known substrate targets and mediates most of the physiological 
effects of insulin, such as glucose uptake (translocation of GLUT 4 to cell membrane), 
protein synthesis (through mTORC1), de novo lipogenesis (increase in ACLY activity) and 
decrease in lipolysis (through degradation of cAMP). 
After insulin binds its receptor it can either be released back into the circulation and cleared 
by either the liver or kidney or degraded after endocytosis of the insulin-receptor complex.   
1.4.2 Insulin resistance 
Insulin resistance can be defined as a condition where cells fail to respond normally to the 
hormone insulin. Despite decades of research into insulin signaling it is still unclear what 
perturbations are causative of insulin resistance. Multiple alterations have been described: 
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decreasing insulin cell membrane receptors, alterations in intracellular signaling cascades, as 
well as post-translational modifications such as reduced phosphorylation of key insulin 
modulating effector enzymes. Likely, insulin resistance is a combination of a multitude of 
these changes.  
Insulin resistance often coexists with hyperinsulinemia, as the pancreas adjusts to higher 
blood glucose levels by releasing more insulin. It is important to note that insulin resistance 
affects cells and tissues heterogeneously, as an example liver insulin resistance will lead to an 
inability of insulin to suppress gluconeogenesis but will not affect de novo lipogenesis [31]. 
Likewise different tissues may be differently affected in selected individuals and there is even 
evidence that developing insulin resistance in one tissue may have knock-on effects of 
inducing insulin resistance in other tissues. Examples include high fat diet fed mice where 
insulin resistance in liver and adipose tissue was found to precede that of muscle [32], and the 
evidence that lipotoxicity plays a key role in development of both muscle and liver insulin 
resistance [33].  
1.4.3 In vivo insulin resistance measurements 
Most commonly, especially in clinical practice, insulin resistance is measured as the inability 
to adequately decrease blood glucose levels at a given insulin concentration and thus 
primarily reflects the inability of insulin to suppress gluconeogenesis from the liver as well as 
GLUT 4 translocation and glucose uptake in adipose tissue and skeletal muscle. Some 
measurement techniques are discussed below. 
1.4.3.1 Hyperinsulinemic euglycemic clamp  
The hyperinsulinemic euglycemic clamp is often referred to as the gold standard technique 
for determining insulin resistance in vivo [34]. It utilizes a continuous high infusion set rate 
of insulin and a concomitant variable glucose infusion to maintain euglycemia. The amount 
of glucose infused is termed the metabolized glucose and is expressed per mg/kg/min (M-
value). Although not a dichotomous measurement, values around 4.7-4.9 have been proposed 
as a cut off for labeling an individual insulin resistant [35, 36]. As the high insulin infusion 
suppresses glucose output from the liver (in order to quantify as precisely as possible how 
much of the glucose taken up by peripheral tissues is due to the glucose infusion), the 
hyperinsulinemic-euglycemic clamp primarily reflects muscle and to some extent adipose 
tissue insulin sensitivity. 
1.4.3.2 Homeostasis Model Assessment of Insulin Resistance  
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a mathematical 
formula used to estimate insulin sensitivity. It is calculated by multiplying fasting plasma 
glucose (mmol/l) with fasting plasma insulin (mU/l) and dividing the result by a factor of 
22.5. Normal HOMA-IR values are around 1, with values over 2.5 deemed insulin resistant 
[37]. As values for insulin and glucose are measured in the fasting state, HOMA-IR primarily 
reflects hepatic insulin resistance. 
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1.4.3.3 Oral Glucose Tolerance Test  
The oral glucose tolerance test is a relatively simple method used clinically to diagnose type 2 
diabetes or gestational diabetes. The test is performed by having a fasting subject consume 75 
grams of liquidized sugar and after two hours have a blood glucose level measured. Values 
between 7.8-11.1 mmol/l correspond to impaired glucose tolerance and values above 11.1 
classify the subject as being diabetic. 
1.5 PATHOPHYSIOLOGY OF PERNICIOUS ADIPOSE TISSUE IN OBESITY 
Adipose tissue dysfunction impacts whole-body metabolism. This is exemplified by 
lipodystrophies, a heterogeneous group of disorders characterized by a varying degree of 
adipose tissue loss despite normal caloric intake. Individuals are prone to both severe insulin 
resistance as well as hypertension [38]. Similar consequences occur if adipose tissue is 
subjected to extended periods of hyper-caloric intake. Subcutaneous adipose tissue depots 
will eventually fail to achieve adequate expansion, and instead fat will be stored ectopically 
[39] in visceral adipose tissue, liver and skeletal muscle, resulting in metabolic disturbances 
[40, 41]. Dysfunctional adipose tissue is characterized by several phenotypic changes such as 
increasing adipocyte size, hypoxia, fibrosis, inflammation and altered lipolysis. 
1.5.1 Adipose tissue expansion 
There seems to exist a numerical set point of adipocytes in humans which is reached in young 
adulthood and retained throughout life, despite a yearly turnover of adipocytes [42]. 
However, when exposed to persistent overfeeding adipocytes will expand both in size and 
number. In general adipocytes increase first in size and then by number, but this varies 
between individuals, and some will have proportionally more cells per amount of adipose 
tissue, hyperplastic adipose tissue, compared to fewer but larger cells, hypertrophic adipose 
tissue. Larger adipocytes have been linked to a wide variety of pernicious metabolic 
consequences [43].  
1.5.2 Hypoxia and fibrosis 
As adipose tissue increases in size and number, depots risk outgrowing their blood supply. 
Hypoxia inducible-factor 1 (HIF-1), an oxygen sensitive transcription factor, activated by 
hypoxia, is upregulated in adipocytes in obesity [44], and is linked to metabolic dysfunction 
[45]. It should be noted that in vivo measurements of obese fat pads show conflicting results 
as whether there is hypoxia in adipose tissue in human tissue [46], while the correlation is 
clear in many animal models [47]. Nevertheless, it seems that oxygen tension levels in 
humans are probably too low for the optimal homeostasis of the adipose tissue depot. 
Hypoxia is furthermore believed to lead to fibrosis, which is distinguished by an increase in 
extracellular matrix (ECM). HIF-1 is deemed to be one culprit, inducing an increased 
production of ECM [45]. The increase in ECM reduces tissue plasticity, further worsening 
adipose tissue function. Fibrosis has been closely linked to an increase in immune cell 




Inflammation has long been known to have a role in dysfunctional adipose tissue [48]. 
Immune cells, especially macrophages, growingly populate obese adipose tissue and give rise 
to a chronic low-grade inflammation which has been linked to metabolic dysregulation [49-
51]. Macrophages have classically been considered to exist in either a more pro-inflammatory 
state or anti-inflammatory state, but there is also evidence of a macrophage subtype in 
adipose tissue with a distinct gene expression profile [52]. As adipose tissue mass expands, 
more pro-inflammatory macrophages populate the fat pad, secreting pro-inflammatory 
cytokines like TNF- α, IL-6 and IL-1β [53]. While inflammation has been classically linked 
to insulin resistance and a pernicious WAT phenotype, it is important to note that it also 
constitutes an important mechanism for adipose tissue remodelling. This has been shown by 
knocking down different inflammatory pathways in mice, which lead to an inability of 
visceral adipose tissue to expand during high fat feeding [54], resulting in ectopic lipid 
accumulation, systemic inflammation, and insulin resistance. Inflammation’s key role in 
adipose tissue remodelling was also shown in humans by blocking il-6 during exercise 
regimes, which led to the intervention group not losing visceral adipose tissue mass [55].  
1.5.4 Lipolysis in obesity 
Lipolysis is altered in obese adipose tissue. It is characterized by an increase in basal 
lipolysis, in part due to increased inflammation which has been shown to act on multiple 
intracellular pathways decreasing the effects of insulin signaling, downregulating lipid 
coating protein perilipins (increasing access for TG hydrolyzing enzymes) and stimulating 
HSL [56]. On the contrary, stimulated lipolysis is blunted [57]. Overall, the net effect in 
obese adipose tissue is an increase of free fatty acids released into the bloodstream, which 
gives rise to insulin resistance as they have lipotoxic effects on both liver and skeletal muscle 
[57, 58].  
1.5.5 Impact on whole-body metabolism 
While WAT only totals about 5% of postprandial glucose uptake, it has a much larger role in 
regulating whole-body glucose metabolism through its effect on liver and skeletal muscle. 
With excess WAT accumulation, and failure to further expand, adipose tissue can no longer 
properly store TG, leading to ectopic TG deposition in both liver and skeletal muscle, 
hallmarks of insulin resistance [59]. The increased basal lipolysis (and insulins inability 
during conditions of insulin resistance to suppress stimulated lipolysis) also gives rise to an 
excess amount of FFA and glycerol which makes its way to the liver promoting 
gluconeogenesis [58], non-alcoholic fatty liver disease and lipotoxic metabolites, further 
exacerbating hepatic insulin resistance [60]. FFA also inhibits insulin-stimulated glucose 
uptake and glycogen production in muscle and instead promotes lipid synthesis [60]. 
 
10 
1.5.6 Pernicious adipose tissue summary 
The pernicious enlarged adipocyte, hypoxic, fibrotic, and immune cell rich adipose tissue 
with chronic low-grade inflammation signals the end of a healthy adipose tissue depot. It is 
no longer able to keep up with the constant stress of hyper-caloric intake, and this impacts 
negatively on whole-body metabolism. Healthy and unhealthy adipose tissue expansion is 
summarized in Figure 3.
 
Hyperplastic expansion Hypertrophic expansion 
↓ Cell number ↑ Cell number and size 
↓ Immune cells ↑ Immune cells 
↓ FFA release ↑ FFA release 
↓ Hypoxia and fibrosis ↑ Hypoxia and fibrosis 
↓ Inflammation ↑ Inflammation  
↑ Insulin sensitivity ↓ Insulin sensitivity 
 
Figure 3. Healthy (left) and unhealthy (right) adipose tissue expansion. Figure modified 
and reprinted with publishers’ permission from Choe SS et al. Adipose Tissue Remodeling: 





1.6.1 Blood pressure  
Blood pressure (BP) is the force applied by the pulse wave on the arterial wall and is 
expressed as a ratio of systole (contracting heart) and diastole (relaxing heart). BP is 
determined by the cardiac output, total vascular peripheral resistance and circulating blood 
volume. This, in turn, is affected by several regulatory systems including sympathetic 
nervous system (SNS) activation, various hormonal systems such as renin-angiotensin-
aldosterone system (RAAS) and natriuretic peptides, sodium intake and the endothelium 
itself [61]. Perturbations in any or a combination of these factors can result in systematically 
elevated blood pressure levels. These factors are discussed below. Blood pressure also tends 
to increase with age, in part due to increasing arterial stiffness and a cumulative exposure to 
pro-hypertensive factors. 
Finally, blood pressure levels measured in isolated human populations remain at 115/75 
mmHg during the entire lifespan but increase if individuals migrate [62, 63]. It is likely that 
blood pressure levels seen in these isolated societies represent what should be considered 
normal when avoiding exposure to modern day living standards, which includes weight gain, 
an unhealthy diet, and a sedentary lifestyle.  
1.6.1.1 Sodium intake 
High serum sodium concentration promotes fluid retention which increases intravascular 
blood volume and thereby BP. Normally, compensatory mechanisms occur to maintain a 
normal blood pressure, such as an increase in pressure natriuresis (enhanced sodium excretion 
by kidneys in response to an increase in perfusion pressure by the increased blood volume) 
and a decrease in vascular tone (due to an increase in the ratio of endothelium vasodilators to 
vasoconstrictive factors). Individuals with e.g., endothelial dysfunction (impaired 
vasodilation in response to stimuli) and a dysfunctional RAAS can become salt sensitive 
resulting in an increase of systolic BP with high salt intake [64]. 
1.6.1.2 Natriuretic Peptides 
Atrial natriuretic peptides (ANP) are stored and released from the cardiac atria in response to 
increasing blood volume, which is sensed by stretch receptors in the atria. ANP lowers BP by 
three mechanisms: vasodilation, increased vascular permeability (shifting fluid to the 
interstitial compartment away from the intravascular space) and increased renal excretion of 
sodium and water [65]. 
1.6.1.3 Endothelium 
The endothelium is essential in controlling total peripheral resistance by controlling the 
contractile state of the arterial tree. There is a continuous secretion of both vasodilators (e.g., 
nitric oxide (NO) and prostacyclin) and vasoconstrictors (e.g., endothelin 1) in response to 
blood flow and induced shear stress. Most cardiovascular risk factors can transform the 
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normal endothelium function to become dysfunctional by induction of inflammation and 
reactive oxygen species [66] and shifting the balance of vasodilators to vasoconstrictors in 
favor of the latter in hypertension [67].  
1.6.1.4 Renin-angiotensin-aldosterone system  
The kidneys play a central role in BP regulation. When blood flow is reduced to the afferent 
arterioles to the kidneys, specialized cells (juxtaglomerular cells), release and cleave a 
hormone, prorenin to the active renin. Renin cleaves angiotensinogen, released from the liver, 
in the bloodstream, into angiotensin I. Angiotensin I is then activated by angiotensin 
converting enzyme, primarily located in the vascular endothelial cells of the lungs, into 
angiotensin II. The net effect of angiotensin II is an increase in systemic blood pressure 
through a variety of effects. There is an increase in total body sodium (by an increase in 
reabsorption in the proximal convoluted tubules in the kidney through an increase in activity 
of a sodium-hydrogen exchanger) and from an increase release of aldosterone from the 
adrenal glands (which inserts luminal NA-channels leading to more sodium absorption). It 
also induces an increase in peripheral vascular resistance by binding angiotensin type I 
receptors inducing smooth muscle cell contraction and vasoconstriction.  
1.6.1.5 Sympathetic nervous system 
Arterial mechanoreceptors, baroreceptors, are placed along the arterial tree (e.g., the carotid 
sinus), and can sense changes in blood flow. When stretched they signal the brain and inhibit 
SNS activation through changes in neurotransmitters epinephrine (from the adrenal medulla) 
and norepinephrine (from nerve terminals). They target adrenergic receptors in arteries (α1 
vasoconstrictor and α2 vasodilatory) and the heart (β1 and β2, primarily affecting heart rate) 
[68]. Moreover, SNS activation of kidneys contributes to sodium reabsorption [69].  
1.6.2 Classifying hypertension 
Systemic arterial hypertension (hereafter referred to as hypertension) is defined by 
systematically elevated blood pressures over a defined cut off value. Actual values depend on 
measurement method and guideline. The most recent European guidelines (published by 
European Society of Cardiology and European Society of Hypertension) for classifying blood 
pressure and hypertension are summarized in Table 1. In general, a diagnosis of hypertension 
should be made using two or more measurements at two or more different time points. Strict 
cut-offs are somewhat arbitrary, as values above even 115/75 confer an increased CVD risk 
[61], but they help inform decision making in clinical practice. Guidelines also emphasize the 
possibility of using ambulatory blood pressure measurements or home blood pressure 
measurements as they may reveal individuals with white coat hypertension (isolated office 
elevated measurements) or masked hypertension (normal office blood pressure readings but 




 Systolic Diastolic 
Optimal <120 <80 
Normal 120-129 80-84 
High normal 130-139 85-89 
Grade 1 hypertension 140-159 90-99 
Grade 2 hypertension 160-179 100-109 
Grade 3 hypertension ≥ 180 ≥ 110 
Isolated systolic hypertension ≥ 140 <90 
Table 1. European Society of Cardiology and European Society of Hypertensions 
guidelines for classifying hypertension. All systolic and diastolic values are measured in 
mmHg. 
1.6.3 Epidemiology 
Hypertension is common, with an estimated adult worldwide prevalence of over 30% [70]. It 
is the single most important risk factor for cardiovascular disease (CVD) and all-cause 
mortality [71].  
Hypertension can be classified as either primary or secondary, depending on the cause. 
Primary hypertension is a result of complex interactions between genes and environment. 
Over 120 different loci have been associated with hypertension [72], but explain very little of 
the variance. Secondary hypertension can be attributed to a specific identifiable cause. They 
include rare monogenic diseases, hormonal emitting tumors or adrenal diseases, renal artery 
stenosis, thyroid disorders, obstructive sleep apnea or drug side effects. Primary hypertension 
constitutes around 90% of cases. 
1.6.4 Hypertension treatment 
Hypertension treatment is based on removing or modifying lifestyle factors, and 
pharmacotherapy. The decision to initiate treatment depends on blood pressure levels, age, 
and future cardiovascular risk. Latest joint guidelines from European Society of Cardiology 
and European Society of Hypertension recommend initiating both lifestyle changes and drug 
treatment in subjects with grade 1 hypertension and above. They also advocate for subjects 
with high normal blood pressure levels who are close to 140/90 mmHg to initiate 
pharmacotherapy if lifestyle changes fail to lower blood pressure [73]. For younger 
individuals with grade 1 hypertension and low cardiovascular risk, there is lacking 
randomized control trial evidence regarding the effectiveness in reducing mortality and 
morbidity with pharmacotherapy. However, many clinicians find it reasonable to initiate 
medical therapy, especially if lifestyle changes fail to lower blood pressure. 
Proven effective lifestyle changes are weight loss, reduced sodium intake, moderating alcohol 
intake, smoking cessation, regular physical exercise and keeping a healthy diet [74-76].  
Meta-analysis of placebo-controlled trials have established reductions in blood pressure 
levels and in cardiovascular mortality and morbidity for five drug classes (beta blockers, 
calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor 
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blockers and diuretics) as equally effective, and should form the basis of hypertension 
pharmacotherapy treatment [76-79]. While minor differences do exist regarding disease 
specific improvements and/or risk reductions [76], the overall effect can be attributed to 
blood pressure levels reduction. However, careful consideration should still be given 
regarding individual co-morbidities and side effects which can influence drug of choice. 
Other drug classes have less randomized clinical trial evidence, or more adverse effects and 
should generally be considered as add on therapies in individuals failing to meet blood 
pressure goals. 
1.6.5 Obesity and hypertension 
The link between obesity and hypertension is well established and results from the 
Framingham heart study suggests that roughly 70% of primary hypertension can in part be 
attributed to excess weight gain [80]. It is important to note that excess weight gain increases 
blood pressures across the entire spectrum [81]. Finally, weight loss reduces blood pressure in 
many subjects [82, 83].  
There are several mechanisms by which obesity contributes to hypertension. Firstly, obesity 
is often accompanied by insulin resistance and hyperinsulinemia, which contributes to 
hypertension. Possible mechanisms will be discussed below. Secondly, several morbidities 
and behaviors which can give rise to increased blood pressure and hypertension are 
commonly seen in obesity. These include sleep apnea, increased dietary salt- and alcohol 
intake and a reduction in physical exercise.  
Lastly, there are obesity- and adipose tissue-specific effects. These include SNS activation 
which has been reported to be higher in obese subjects [84, 85]. Although obese individuals 
display an increase in heart rate, this seems more related to a decrease in parasympathetic 
activity [86, 87]. Obesity is also characterized by an increase in both extracellular volume and 
blood flow. The blood flow increase is seen in adipose tissue but also other tissues such as 
skeletal muscle, kidneys and heart [88]. Pressure natriuresis is impaired in obesity due to a 
higher resorption of sodium and increase in extracellular fluid volume. This, in turn, is likely 
due to different factors: an increase in SNS specifically in the renal nerves leading to renin 
secretion and sodium resorption, visceral adipose tissue compressing kidneys and activation 
of the RAAS [81]. RAAS activation can be due to kidney compression by adipose tissue but 
there is also RAAS production in the adipose tissue [89]. However, there have been no 
confirmatory studies to date suggesting it would have causative roll in blood pressure 
changes. Intake and infusion of fat has been linked to sensitizing peripheral alfa-1 adrenergic 
stimulation and increased vascular tone [90, 91]. Natriuretic peptides have also been found to 
be lower with increasing BMI [92]. Lastly, there seems to be an inadequate release of 




1.6.6 Insulin resistance and hypertension 
The insulin receptor is expressed in vasculature [94], where it has been shown to stimulate 
the production of NO (a potent vasodilator), by phosphorylating endothelial nitric oxide 
synthase (eNOS), increasing its activity [95]. This pathway is likely inhibited in the setting of 
insulin resistance. It also stimulates the production of endothelium-1, a potent vasoconstrictor 
and this effect may be even more pronounced in insulin resistance [96]. Insulin has been 
found to increase vasoconstriction after administration in the setting of severe insulin 
resistance [97]. Chronic hyperinsulinemia has also been reported to impair the otherwise 
vasodilatory action of insulin [98] and not improve endothelial function [99].  
Obesity is associated with a change in adipokine secretion profile. Many of these could play a 
role in the development or maintenance of hypertension. For example leptin secretion is 
augmented in obesity and chronic infusion in rodents was followed by an increase in blood 
pressure [100]. However, there was no change when administered in humans [101]. 
Adiponectin secretion diminishes with increasing adiposity and adiponectin has been shown 
to restore eNOS [102]. Inflammation has been linked to hypertension and a hallmark of obese 
adipose tissue is immune cell infiltration. These immune cells release many pro-inflammatory 
cytokines, for example TNF-α, MCP-1 and IL-6, which are believed to play a role in 
hypertension [103]. In keeping with this, TNF-α antagonist treatment has been shown to 
hinder the development of hypertension in fructose challenged rodents [104]. Here, the 
perivascular adipose tissue may be of extra importance due to its anatomical location; it can 
be postulated that any detrimental changes to this depot in obesity will highly influence 
vascular health. It has been suggested that this adipose site has a different expression profile 
compared to other adipose tissue depots [105], and that there is a significant amount of cross-
talk between PVAT and blood vessels with reciprocal effects on both tissues [106].  
1.7 ARTERIAL STIFFNESS 
The reduced arterial capacity to expand and contract with given changes in volume is termed 
arterial stiffness. Healthy vessels distend when the systolic pulse wave hits the arterial wall 
and then contract in the diastolic phase. This leads to a decrease in systolic pressure and 
increase in diastolic pressure. In stiff arteries the capacity for distention and contraction is 
limited (Figure 4), and instead there is widening of the pulse pressure, the difference between 
systolic and diastolic pressure. Furthermore, with increasing pulse wave velocity, waves 
reflected from peripheral circulation (mainly from bifurcations) return while the heart is still 
in systole, adding pressure to the systolic phase. This results in the left ventricle working 
harder against a higher pressure, increasing oxygen demand, leading to left ventricle 
hyperplasia. Stiffening also leads to arterial wall remodeling, causing stenosis and plaque 
build-up [107]. Arterial stiffness is an independent risk factor for CVD and all-cause 
mortality [108].  
The simplified molecular basis of arterial stiffness is a disturbance in the ratio between the 
two most important scaffolding proteins in the arterial vessel wall, collagen, and elastin. 
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Normally the relative contribution of these two proteins is held stable but due to a pro-
inflammatory environment there is an abnormal production of the stiffer collagen and a 
diminishing abundance of elastin, limiting the distensibility of the vessel [109]. There is a 
thickening of intima-media and infiltration of vascular smooth muscle cells, immune cells, 
increased matrix metalloproteinases, and cytokines [110, 111]. The stiffening is often patchy 
and occurs mainly in central arteries [112]. Known risk factors affecting arterial stiffness are 
age, pulse, blood pressure (note, arterial stiffness is a risk factor for hypertension and arterial 
stiffness precedes hypertension, but can then be exacerbated by high blood pressure) [113]. 
Finally, smoking and physical exercise also play a part [114, 115].  
1.7.1 Measuring arterial stiffness and vascular health 
The easiest and most accessible way to assess arterial stiffness is to measure the pulse 
pressure, which is the difference between systolic and diastolic blood pressure. Only a normal 
blood pressure device is necessary. One drawback is that peripheral measured pulse pressures 
can differ up to 20 mmHg from central pulse pressures [116].  
Another non-invasive method is to measure the speed of the pulse wave between two points 
and divide the result with the travel time. The result is pulse wave velocity (PWV). Arteries 
that cannot extend during systole will result in an increased speed of the pulse wave travelling 
down the circulatory system, the stiffer the artery the faster the PWV. Most commonly this is 
measured either by different pressure sensor devices or doppler probes placed at one or 
different points in the body, but it is also possible to use oscillometric measures which 
capture both the systolic and reflected wave to calculate PWV. PWV measures have been 
used in many studies to predict long term consequences of arterial stiffness, and aortic PWV 
is an independent predictor of a variety of outcomes in different populations [107]. The PWV 
between the carotid and femoral artery has been deemed the gold-standard measurement of 
arterial stiffness [107].  
 
Figure 4. Elastic and stiff arteries. Elastic arteries (left) expand upon force from the systolic 
pulse wave, lowering systolic blood pressure and reducing the speed of the pulse wave. In 




1.7.2 Obesity and arterial stiffness 
Body weight gain increases arterial stiffness [117]. Short, moderate, and long-term weight 
loss have all been found to improve arterial stiffness [118-121]. Several studies have explored 
the underlying causes. Positive associations between arterial stiffness and several adipose and 
obesity factors have been found: adipokine secretion from WAT [122], insulin resistance 
[123], WAT distribution [124], inflammation [125], visceral adipocyte volume [126] and 
circulating levels of free fatty acids [127] have been reported in cross sectional settings. 
Furthermore, associations between carotid–femoral PWV and Hemoglobin A1c levels, [128] 
and between aortic PWV and central obesity, plasma adiponectin, and TG levels have been 
seen in longitudinal observational studies [129]. Taken together, these studies suggest a 
possible causal relationship between perturbed WAT and arterial stiffness. 
Candidate gene- and genome-wide association studies have determined genes whose 
expression associates with arterial stiffness [130]. In obese WAT one of these genes’ 
expression, COL4A1, was associated with improvement in aortic PWV following extensive 
weight loss [121].  
1.8 CONCLUDING REMARKS 
Obesity is a large and growing public health concern. It’s characterized by an expanding 
adipose tissue mass which often is dysfunctional and linked to both metabolic and vascular 
disease. The mechanisms are complex but once understood should hopefully offer further 




2 RESEARCH AIMS 
The overarching aim of this thesis is to establish which specific WAT factors associate with 
arterial vascular disease and to investigate the lipolytic effect of ANP in obese WAT. 
2.1 SPECIFIC AIMS 
2.1.1 Study I 
To determine the relationship between arterial stiffness and anthropometric measurements 
and adipocyte volume and number in obesity. 
2.1.2 Study II 
To establish if weight loss leads to long term improvement in arterial stiffness, and if any 
WAT factors can predict changes in PWV after significant weight loss. 
2.1.3 Study III 
To determine if any WAT factors differ between subjects who improve in BP and those who 
do not, following significant weight loss.  
2.1.4 Study IV  




3 MATERIALS AND METHODS 
3.1 STUDY DESIGN AND SUBJECTS 
Participants for all studies were from the NEFA (Non-Esterified Fatty Acid Adipose Factors 
Behind Insulin Sensitivity clinical trial, NCT01727245) cohort. The NEFA study is an 
interventional non-randomized clinical trial assessing the effects of weight loss on insulin 
sensitivity, body composition and vascular function. Participants were obese individuals who 
voluntarily sought gastric bypass surgery for primarily cosmetic reasons and were recruited 
from surgical clinics. Also, Study IV included non-obese controls who were recruited from 
advertisements. 
Inclusion criteria was BMI of 30 or above, age between 18 to 60 years, and being scheduled 
to undergo bariatric surgery by laparoscopic RYGB technique. Exclusion criteria was a 
diagnosis of diabetes mellitus type 2 with insulin treatment and/or glitazones, oral or 
parenteral steroid treatment, complicated psychiatric disease, and the use of warfarin. 
In Study I we included all obese trial subjects where PWV data was available. In Study II we 
included all obese individuals where two-year follow-up data was available but excluded 
individuals on anti-hypertensive medication. In Study III we included all female obese 
individuals on pharmacotherapy for hypertension as well as female subjects with two-time 
points measurements over 140 mmHg systolic and/or 90 mmHg diastolic blood pressure at 
baseline. Finally in Study IV we included all available obese and non-obese women. For this 
study we also included data from our collaborators in France who recruited a cohort of lean 
and overweight men.  
3.1.1 Bariatric surgery 
All obese subjects underwent RYGB surgery at either Ersta or Danderyd Hospital in 
Stockholm, Sweden.  
3.2 SUBJECT PHENOTYPING 
All examinations listed below were collected during a single visit (per time point) at our 
clinical laboratory, which employed the same research nurses and laboratory technicians 
during the entire trial period. Subjects had been instructed to fast, including caffeine and 
nicotine, from 22:00 the preceding evening. 
3.2.1 Dual energy x-ray absorptiometry  
To determine body composition of different adipose tissue depots: android and gynoid 
regions as well as estimated visceral adipose tissue (EVAT) and estimated subcutaneous 
adipose tissue (ESAT), subjects underwent a dual energy X-ray absorptiometry (DXA) scan. 
A GE Lunar iDXA from GE Healthcare, Madison, WI, USA, was used for all examinations. 
It utilizes a software (enCORE software, version 14.10.022, GE Healthcare, Madison, WI, 
USA) to determine android and gynoid fat from pre-determined anatomical markers. 
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Furthermore, we utilized another software (Corescan, GE Medical Systems, Chalfont St. 
Giles, UK) to determine visceral fat mass in the android region defined by enCORE. ESAT 
(in the android region) was calculated by subtracting EVAT from total android fat. The use of 
DXA to determine visceral fat mass has been approved by the US food and drug 
administration and correlates excellently (r2⩾0.95) with computer tomography values [131]. 
Finally, additional advantages are that the method exposes individuals to a very low dose 
radiation and is easy to use, especially for obese patients. 
3.2.2 Hyperinsulinemic euglycemic clamp 
As previously mentioned, hyperinsulinemic euglycemic clamp is considered the gold 
standard in vivo measurement of insulin sensitivity, reflecting primarily that of skeletal 
muscle and to some degree, adipose tissue. We administered a 1,6 units bolus dose of insulin 
(Actrapid, Novo Nordisk, Copenhagen, Denmark) per square meter of body surface area. 
This was followed by a continuous two-hour infusion of intravenous insulin at a rate of 0,12 
units/m2 body surface area per minute. Insulin was diluted with 2 ml albumin (200 g/l, 
Albunorm Octapharma, Stockholm, Sweden), 82 ml sodium chloride (9 mg/ml) and, to avoid 
hypokalemia, 16 ml potassium chloride (2 mmol/ml). Concomitantly, a variable infusion of 
glucose (200mg/ml) was administered to keep blood glucose between 4.5-5.5 mmol/L. Blood 
glucose values were determined from samples drawn from the dorsal side of a hand which 
kept in a 63 °C heated box. Samples were drawn in pairs, with the average of the two results 
recorded every fifth minute and analyzed on a Hemocue (Ängelholm, Sweden). 
Glucose infusion rates during the second hour of the clamp was used to determine the glucose 
disposal rates (M-value; mg/kg*min). Since a relatively high insulin dose was administered 
during the clamp, we assumed that hepatic glucose output was non-existent, and the glucose 
infusion rate reflected peripheral tissue glucose uptake. 
3.2.3 Biochemistry 
Fasting blood glucose samples were drawn for routine clinical chemistry measurements. We 
analyzed: creatinine, glucose, thyroid stimulating hormone, total cholesterol, TGs, high 
density lipoprotein, apolipoprotein a, apolipoprotein b, aspartataminotransferas, 
alaninaminotransferas, glutamyltransferas, hemoglobin A1c, calcium, albumin. 25-oh d 
vitamin, and c-reactive protein. An accredited university hospital laboratory (Karolinska 
University hospital) performed all the analysis. 
3.2.4 Blood pressure measurements 
Blood pressure was measured after a 15-minute rest with subjects in the supine position, 
using an automated device (Omron M10-IT, Omron Health Care, Hoofddorp, the 
Netherlands). Two measurements were taken, and if they differed significantly, a third 
measurement was obtained.  
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3.2.5 Aortic pulse wave velocity 
Aortic PWV (hereafter referred to as PWV, as no other PWV was measured in these studies) 
was recorded with an oscillometric device (Arteriograph, TensioMed, Budapest, Hungary). 
Cuff size was based on the subject’s arm circumference at the time of examination. PWV was 
calculated by dividing the pulse wave traveled distance (suprasternal notch to the pubic 
bone), with the transit time (RT/2). Distance was measured in a straight line next to the 
subject to avoid any influence from the abdominal circumference. Final values were the mean 
of 3 measurements. Recommended standardized procedures for obtaining pulse wave 
velocity measurements were followed [132].  
The Arteriograph provides other vascular measures that were recorded: augmentation index 
which is the percentage of central pulse pressure attributed to the reflected wave from the 
periphery, pulse pressure the difference between systolic and diastolic blood pressure, (PP) 
and the central systolic blood pressure. 
3.2.6 Questionnaire and interview 
Subject history with regards to medications, physical exercise and tobacco use was captured 
by written questionnaire and confirmed by interview. Physical exercise was graded on a four-
point incremental scale with 1 = no regular exercise, 2 = light exercise sometimes 3 = regular 
physical exercise regime several times a week and 4 = near daily physical exercise. 
3.2.7 Adipose tissue biopsies 
Visceral adipose tissue biopsies were collected during bariatric surgery (from the greater 
omentum). Subcutaneous adipose tissue biopsies were taken by needle biopsy before (fasting 
state) and after the two-hour hyperinsulinemic euglycemic clamp (hyperinsulinemic state). 
Biopsies were taken laterally of the umbilicus after an injection of lidocaine. Using a needle 
and 10 ml syringe, adipose tissue was extracted by negative pressure. The aspirated fat was 
rinsed over a plastic filter with sodium chloride. Coagulated blood was manually removed by 
the use of forceps or plastic spatula. Unlike samples obtained during general surgery, needle 
aspirations have been shown to not impact on adipose metabolism or lipolysis [133].  
3.3 EX VIVO PHENOTYPING 
Adipose tissue samples were transported in sodium chloride to the laboratory immediately 
after biopsies were obtained. At the laboratory samples were washed both in sodium chloride 
and then with washing buffers (Krebs Ringer Phosphate buffer with 1 % and 0.1% 
concentration bovine serum albumin). Mature adipocytes were separated from the stromal 
vascular fraction by incubation in a 37°C water bath with 0,5mg/ml collagenase and 4% 
bovine serum albumin for 60 minutes. Adipocytes were then washed again (with the previous 
washing buffer) and subsequently filtered through a nylon filter three times. 
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3.3.1 Adipocyte measurements 
Adipocyte diameter was determined in accordance with previously established methods 
[134]. A droplet from the adipocyte suspension was placed on a cover slide and examined 
under direct light microscopy. The diameter of 100 cells were counted with a ruler in the 
ocular of the microscope. As adipocytes are spheric, the mean adipocyte volume was 
approximated using a well-established formula [135]. Approximations have been found to 
correlate well with adipocyte size from sectioned adipose tissue [136].  
The average density of TGs (here defined as triolein, a TG formed from glycerol esterified 
with three oleic acids) is 0.915 g/cm3 and this number was multiplied with adipocyte volume 
to calculate adipocyte weight. To determine adipocyte number, adipocyte mass was divided 
by the adipocyte weight.  
3.3.2 Lipolysis 
Isolated adipocytes were suspended in Krebs-Ringer phosphate buffer (pH 7.4) and bovine 
serum albumin (20mg/ml), ascorbic acid (0.1mg/ml) and glucose (1mg/ml). They were 
incubated with or without various concentrations of isoprenaline, ANP, dobutamine or 
terbutaline in a shaking water bath set at 37 °C for two hours. Afterwards samples were 
placed on ice to stop lipolysis. An adipocyte free aliquot was taken for glycerol 
measurements. Glycerol concentrations in absence of lipolytic stimulating hormone are 
considered basal lipolysis and glycerol concentrations with highest concentration of lipolytic 
agent are termed stimulated lipolysis. Glycerol is measured since adipocytes lack glycerol 
kinase and thus cannot reuse glycerol. Lipolysis can be expressed per cell, per gram lipid or 
as a ratio of stimulated over basal lipolysis.  
3.3.3 Microdialysis 
Microdialysis is a minimally invasive sampling technique that permits both delivery of an 
agent into tissue and measurement of any free unbound analyte from the extracellular space. 
In Study IV microdialysis was used to assess in situ lipolytic response to ANP. Lidocaine 
(200 ul 1%) was injected subcutaneously ten cm laterally of the umbilicus in a cohort of 16 
men (seven lean and nine overweight), after which a Microdialysis probe (Carnegie 
Medicine, Stockholm, Sweden) connected to a microinjection pump (Harvard apparatus, Les 
Ulis, France) was inserted. The probe membrane has a size of 20 x 0.5 mm and a 20-kDa 
molecular-weight cutoff.  
Ringer solution (139 mmol l−1 sodium, 2.7 mmol l−1 potassium, 0.9 mmol l−1 calcium and 
140.5 mmol l−1 chloride) containing 10 μmol l−1 hANP (human α-ANP1-28) (Clinalpha, 
Laüfelfingen, Switzerland) was infused together ethanol supplementation, to estimate 
changes in WAT blood flow around the probe, using an ethanol escape method [137]. First 
only a ringer solution with ethanol was infused but after a 60-minute equilibration period 
hANP was added for 60 minutes. 15-minute fractions were collected during both infusion and 
recovery period. Ethanol in both perfusate and dialysate was analyzed with an enzymatic 
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method [138]. Glycerol in dialysate was determined with an ultrasensitive radiometric 
method [139].  
3.3.4 Western blot 
For identifying alterations in the ANP lipolytic signaling cascade in Study IV, subcutaneous 
adipose tissue protein was isolated and analyzed in a subgroup from cohort 1 (16 non obese 
and 27 obese subjects). In 200-600 ul RIPA buffer and protease inhibitor cocktail set V 
(Calbiochem EMD Chemicals, Darmstadt, Germany) a small amount of adipose tissue (100-
300mg) was homogenized (IKA T10 basic ULTRA-TURRAX, IKA-Werke Chemicals, 
Darmstadt, Germany) on ice. Lysates were centrifuged at 14000 rpm for 20 minutes at 4 °C. 
The infranatant was transferred to new tubes and protein concentrations were determined 
using Pierce BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). 
On 10% polyacrylamide gels, 50 μg of protein was separated overnight and then blotted onto 
polyvinylidene difluoride membranes (Amersham Hybond, GE Healthcare, 
Buckinghamshire, UK) using electroblotting. Membranes were then washed in Tris-buffered 
saline with 0.1% Tween 20 (TBS-T), 0.35 M NaCl and blocked with TBS-T containing 3% 
ECL Advance Blocking Agent (GE Healthcare) for one hour. Overnight at 4 °C membranes 
were incubated with primary antibodies and blocking solution. Next day, following repeated 
wash steps, blots were incubated with secondary antibodies at room temperature for one hour. 
Antibodies used were primary; α-NPRC (Sigma-Aldrich, St Louis, MO, USA; SAB2501867, 
1:1000 dilution); α-NPRA (Abcam, Cambridge, UK; ab154266, 1:1000 dilution); α-PDE5A 
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA; SC-32884, 1:500 dilution); α-cGKI 
(Abcam ab90502, 1:1000 dilution); and α-beta actin (SigmaAldrich A2066, 1:2000 dilution) 
and secondary were horseradish peroxidase-conjugated-IgG or α-goat or α-rabbit (Sigma-
Aldrich). To avoid bands overlapping with background signals membranes were incubated 
with one primary antibody at a time, in the order listed above. Finally, membranes were 
washed with TBS-T and chemiluminescence (Amersham ECL Advance Western Blotting 
Detection Kit, GE Healthcare) was used to detect protein in a Chemidoc XRS system (Bio-
Rad Laboratories, Hercules, CA, USA) using Quantity One software. 
3.3.5 RNA sequencing 
In order to further characterize adipose tissue phenotype we analyzed gene expression by 
RNA sequencing in Study II and III. We utilized cap analysis gene expression (CAGE), an 
RNA sequencing technique. 
Adipose RNA was extracted with RNeasy Lipid Tissue Mini Kit (QIAGEN). RNA 
concentrations were measured (Nanodrop NP-1000) and quality determined by a bioanalyzer 
RNA 6000 Pico Kit (Agilent Technologies). Next CAGE libraries were prepared by reverse 
transcribing mRNA to cDNA, adding a linker and amplifying transcripts by PCR and then 
sequenced using Illumina Hi-Seq 2500 or 2000 [140]. Sequenced reads were mapped to the 
human genome using Bowtie [141]. Output is tags per million, i.e., how many individual 
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transcripts from every specific gene that is found in the sample. Results were normalized and 
genes with low expression counts excluded.  
In Study III we analyzed insulin induced transcriptomics. Here, gene expression was 
compared in two different biopsies, one taken during fasting and the next after a two-hour 
insulin infusion during the hyperinsulinemic euglycemic clamp. Gene expression was then 
compared between fasting and hyperinsulinemic samples and a gene was considered to be 
regulated by insulin if there was a significant increase or decrease in expression between 
conditions. 
3.4 ETHICAL CONSIDERATIONS 
Research always holds the promise of alleviating or even curing disease. However, most 
research offers this hope only for future, not current patients. Thus, any risks to subjects 
taking part in research must be limited.  
Subjects enrolled in the clinical trial these results stem from, voluntarily agreed to take part 
and signed an informed consent. The trial underwent ethical review and was granted 
permission to proceed by a hospital appointed multidisciplinary board. The trial adhered to 
the principles outlined in the Declaration of Helsinki. Nevertheless, subjects in the trial were 
exposed to several risks. 
Firstly, subjects underwent a DXA examination which exposes them to radiation. The 
amount of radiation is however equal to only one day of background radiation which in 
practice can be considered harmless. A permit was granted from a local authority 
(Strålsäkerhetsmyndigheten) for subjects to undergo the DXA examination. 
Subjects also underwent one or several subcutaneous adipose tissue needle biopsies. This 
yields a local hematoma and some discomfort after the effect of local anesthesia dissipates. 
There is also a risk of infection or in theory more extensive bleeding, however our clinical 
research unit has now taken well over 2000 biopsies without any major complication. 
Blood testing was also done, with the potential of uncovering previously unknown disease or 
ambiguous results in need of monitoring or more extensive testing. We took steps to follow-
up any abnormalities by having a medical doctor review all results and referring for future 
care if needed.  
Also, by agreeing to take part in a study, medical information is revealed and stored. To 
ensure anonymity all subject data was coded and kept separate from any personally 
identifying information.  
Finally, individuals have the right to at any time, and without question, withdraw from the 




Unless otherwise stated, all values in this thesis and included studies are presented as mean ± 
standard deviations. Normal distribution was assessed by Shapiro-Wilks’s test.  
Study I. All variables were compared with simple linear regression to PWV. Analysis of 
covariance was performed for the effect of gender on the relationship between visceral or 
subcutaneous adipocyte volume and PWV. Also, the relationship between either visceral or 
subcutaneous adipocyte volume, and PWV (set as the dependent variable) and another single 
variable were determined by multiple regression. Finally, a multiple regression model was 
performed with PWV as the dependent variable and stepwise removal of non-significant 
regressors.   
Study II.  Variables before and after weight loss were, if normally distributed, compared with 
paired-sample Student t test (two-tailed), and, if non-normally distributed, the related-samples 
Wilcoxon signed–rank test. Baseline adipose and metabolic variables were set as independent 
variables and single regression was performed with changes in PWV as the dependent 
variable. Finally multiple regression analysis with either subcutaneous adipocyte volume or 
expression of COL41A set as the independent variable and PWV as the dependent variable 
were done. Models were adjusted for known determinants of arterial stiffness. 
Study III. Variables were compared using unpaired Student’s t-test (two-tailed). 
Study IV. Variables between obese and non-obese individuals were compared with unpaired 
Student’s t-test. Paired Student’s t-test was used when comparing obese subjects before and 
after weight loss. When assessing glycerol response in the microdialysis experiment, a two-
way repeated measure of analysis of variance was done. Finally, the relationship between 
hormone induced lipolysis and clinical variables was assessed by spearman rank correlation, 
and multiple regression. A power calculation was performed indicating 80% power to detect 







Detailed results are available in each respective paper and manuscript. The most notable 
results are summarized here. 
4.1.1 Study I 
Arterial stiffness has been found to be increased in obese individuals, but it is more 
prominent in individuals with central as opposed to a peripheral accumulation of adipose 
tissue [124, 142]. Furthermore, an increase in individual adipocyte size is correlated to insulin 
sensitivity and risk of developing type 2 diabetes [143-145]. Moreover, specific increase in 
visceral adipose cell size is linked to dyslipidemia, while the same phenotype in subcutaneous 
adipose tissue correlates with insulin sensitivity [146]. We explored the association between 
PWV and adipocyte size and number in both the visceral and subcutaneous adipose depot in a 
cohort of 120 obese individuals. Subjects underwent extensive phenotyping (see above 
methods section). 
Average cohort aPWV was 8.13 ±1.9 m/s. Individual associations between clinical variables 
and PWV are displayed in Table 2. 
 
Table 2. Clinical characteristics and their correlation with PWV in Study I 
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The study confirmed several previous known associations between PWV and vascular 
parameters such as systolic and diastolic blood pressure and pulse rate. We also confirmed 
correlations between measures of central adiposity, waist hip ratio and visceral fat mass and 
PWV, while no such significant associations existed for BMI, total body fat or subcutaneous 
fat mass. Regarding adipocyte volume, a positive association was found for both visceral and 
subcutaneous adipocyte volume. To explore this relationship further and adjust for 
confounders we ran a multiple regression model (Table 3) including all factors that associated 
with PWV in Table 2.  
This demonstrated that, after adjusting for relevant confounders, only visceral adipocyte 
volume associated significantly with PWV. 
 
Table 3. Factors contributing to variations in PWV in Study I. Note, Std Betaa is an incorrect 
term, values in this column are the partial R2 of each variable.  
4.1.2 Study II 
Short and moderate term weight loss (< one year) leads to improvement in arterial stiffness 
[118]. It is still unknown if changes last long term and what adipose tissue factor, if any, can 
predict improvement. For this study we analyzed 82 subjects before and two years after 
RYGB surgery, excluding subjects with anti-hypertensive pharmacotherapy and one 
individual with a faulty PWV measurement.  
We found that pronounced weight loss due to bariatric surgery led to a small but lasting 
improvement in PWV 7.80 ±1.50 VS m/s vs 7.23 m/S ±1.41, p = 0.006). As expected, 
subjects also improved significantly in all measured metabolic and adipose outcomes.  
To find WAT predictors of improvements in PWV following significant weight loss we 
performed linear regressions between change in PWV (dependent variable) and adipose and 
metabolic variables (independent variables). Results are displayed in Table 4, and after 




Table 4. Relationship between individual factors and changes in PWV. 
With subcutaneous adipocyte volume being the only adipose factor able to predict 
improvements in our cohort, we also wanted to establish if the relationship remained 
significant after adjusting for known arterial stiffness confounders. Thus, we created two 
multiple regression models, adjusting for systolic blood pressure and resting pulse rate in 
model 1 and systolic and diastolic blood pressure, resting pulse rate, age, sex, smoking status, 
and self-reported exercise in model 2. Results are displayed in Table 5. 
 
Table 5. Multiple linear regression between subcutaneous adipocyte volume and PWV in two 
different models in Study II. 
We also performed RNA sequencing on a subgroup of individuals and wanted to investigate 
if individual WAT gene expression could predict improvements in PWV. After correcting for 
multiple testing, a global analysis found no significant associations. However, when we used 
a pre-selected list of genes previously associated with arterial stiffness [147], COL4A1 could 
in our cohort predict improvements in PWV following significant weight loss. The 
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relationship remained significant also after adjusting for the same confounders in the previous 
model 1 and 2.  
In summary, we found that significant weight loss leads to sustained improvements in arterial 
stiffness and that it can be predicted both by baseline subcutaneous adipocyte volume and 
specific WAT gene expression. 
4.1.3 Study III 
Weight loss through bariatric surgery can lead to hypertension improvement and even 
remission in some but not all individuals [14]. There is also a link between insulin resistance 
and hypertension [148]. We aimed to identify if there were WAT or metabolic differences 
between those who improved in blood pressure compared to those who did not, after 
significant weight loss. We included all hypertensive females with multiple blood pressure 
readings and available transcriptomic data.  
We defined hypertension as having multiple blood pressure readings (at different timepoints) 
at or above 140 mmHg systolic BP or 90 mmHg diastolic BP, or treatment with anti-
hypertensive pharmacotherapy. In order to have access to blood pressure readings at more 
than one timepoint (i.e., at our research laboratory) we collected data from the surgical 
outpatient clinics subjects attended as part of their standard medical care before and after their 
bariatric surgery. In total, 18 women were included, ten who improved after weight loss and 
eight did not. 
To determine which factors could potentially predict blood pressure improvement after 
significant weight loss we compared multiple variables between the two groups. While the 
improved group was significantly younger (44±5 vs. 51±7, p =0.03), no other parameter 
differed between the groups. On a transcriptomic level there were no differences in fasting 
WAT gene expression between the groups.  
To investigate the role of insulin resistance and hypertension, we compared insulin resistance 
in multiple peripheral tissues between the two groups. Again, there was no difference in 
skeletal muscle insulin resistance (as exemplified by glucose uptake during the 
hyperinsulinemic euglycemic clamp) or hepatic insulin resistance (measured by HOMA), 
with both groups starting at a similar level and improving equally after weight loss in both 
parameters. However, adipose tissue insulin sensitivity, in this study defined as insulin 
induced gene expression, displayed large differences with 29 genes regulated by insulin at 
baseline in the non-improved versus 95 in the improved group. At two years the non-
improved group only had 31 genes regulated by insulin despite significant weight loss. This 
contrasted with the improved group where 185 genes where significantly regulated. 
Altogether this suggests a model where insulin resistance needs to be alleviated in all 
peripheral tissues for hypertension to remit or improve. 
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4.1.4 Study IV 
In man there are two primary hormones that stimulate lipolysis: catecholamines and ANP. 
While catecholamines are well studied, with a blunted response seen in obesity (when 
measured per g lipid or as a ratio of stimulated over basal) [149], the lipolytic effect of ANP 
has yet to be studied in obese adipose tissue. To this end we characterized the effect both in 
situ and in vitro effect of ANP on adipocyte lipolysis. 
For the in vitro studies, adipocytes obtained from abdominal subcutaneous needle biopsies 
from 122 subjects (both obese and non-obese) were subjected to lipolysis measurements 
either spontaneous (no hormonal stimulation) or after the presence of various lipolytic 
hormones, i.e., stimulated lipolysis. Fifty-two of the women were reinvestigated two years 
after bariatric surgery (all available subjects at the time of data collection). Results showed 
that ANP stimulated lipolysis was decreased in the obese when measuring per g lipid 
(2.9±1.4 vs 1.6±0.9 p =0.0001) and when expressed as a ratio of stimulated over basal 
lipolysis (12.1±10.1 vs 5.7±3.5 p =0.0001). Noticeably, unlike isoprenaline stimulated 
lipolysis, there was no increase in stimulated lipolysis when measuring per cell. Further 
underscoring the blunting effects of obesity was the increase in stimulated lipolysis after 
weight loss, with subjects improved in ANP stimulated lipolysis both when measured per g 
lipid (1.5±0.8 vs 4.2± 2.9 p =0.0001) or as a ratio of stimulated over basal (5.3±2.9 vs 13.3± 
7.9 p =0.0001).  
In situ glycerol assessments in subcutaneous adipose tissue in lean and overweight men after 
hANP delivery by microdialysis, demonstrated a lower response in the overweight men 
compared to lean (Figure 5). 
We then assessed if we could determine which part of the lipolytic signaling cascade was 
altered in obesity. ANP can either bind to a cell membrane receptor NPRA (encoded by the 
NPR1 gene) leading to a signaling cascade which induces lipolysis, or to a clearance receptor 
NPRC (encoded by the NPR3 gene). Using a previously published dataset of 56 non-obese 
and obese women [150], we found that the expression of several genes were altered in 
obesity. In the obese subjects NPR1 levels were reduced (0.81, false discovery rate 5%) while 
NPR3 were increased (1.42, false discovery rate 1%). We went on to corroborate this at a 
protein level in a subgroup (n=43) of the 122 women and found that NPRA was reduced in 





Figure 5. ANP stimulated lipolysis is impaired in subcutaneous adipose tissue in overweight 
men. A, extracellular glycerol concentrations (EGC) at baseline and after localized infusion 
of hANP (10µmol/l -1, rate 2,5 µl min-1) in abdominal subcutaneous adipose tissue in seven 
lean and nine overweight individuals. B, Area under curve (AUC) analysis of EGC. Student’s 
T-test was used in both A and B. *p = < 0.05 **p = < 0.01 
 
Figure 6. Protein expression of ANP-signaling proteins in human white adipose tissue in lean 
and obese individuals. A, (upper) representative example of lean and obese protein amount of 
NPRA and Actin (control). (lower) Quantified NPRA protein concentration of lean and obese 
subjects. B, (upper) representative example of lean and obese protein amount of NPRC and 
Actin (control). (lower) Quantified protein concentration of lean and obese subjects. 
Statistical comparisons were made using Student’s t-test (unpaired). 
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In summary we established that ANP stimulated lipolysis is blunted in obesity and likely this 






5.1 STUDY SPECIFIC ASPECTS 
5.1.1 Study I  
This study confirmed the relationship between central fat mass and arterial stiffness. 
However, we found that this association was due to visceral adipocyte volume, independently 
of actual fat mass. It remained significant also after adjusting for other well-known factors 
that influence arterial stiffness. The study was cross sectional so it’s important to note it 
cannot prove causality but nevertheless mechanisms can be proposed to be investigated in 
future studies. 
Depot specific gene expression may impact on results. The RAAS plays a role in the 
development of arterial stiffness [151], and visceral adipose tissue secretes most of the 
components and has pronounced activity of this system [152, 153]. Inflammation is also 
linked to arterial stiffness [154], and adipocyte size correlates positively with pro-
inflammatory TNF-α secretion [155].  
FFA have previously been linked to decreased aortic distensibility [156], and large adipocytes 
are known to have a higher level of spontaneous lipolysis, and thus FFA release [157, 158]. 
However, it should be noted that during fasting conditions in our study we found no 
association between serum FFA and PWV.  
Finally, insulin resistance associates with arterial stiffness [123] (insulin sensitivity also 
associated inversely by single linear regression in our study) and both visceral and 
subcutaneous adipocyte size associate negatively with insulin sensitivity [146, 159]. 
Furthermore, adipocytes from individuals with arterial stiffness have been shown to have 
reduced levels of Insulin Receptor Substrate-1 [160], one important enzyme in the insulin 
signaling cascade.  
In summary, several mechanisms may explain the association between visceral adipocyte size 
and arterial stiffness. 
5.1.2 Study II 
Study II demonstrated that weight loss led to long term improvements in PWV, with a 
reduction of on average 0.58 m/s. This change may seem small, but in fact lowered mean 
PWV to that of a healthy reference population [161]. The effect is also larger than what is 
seen after exercise interventions [162], and likely is clinically relevant as a rise in PWV by 
1m/s increases mortality by 15% [108].  
Furthermore, the study again showed that fat mass per se does not seem to be an important 
WAT factor with regards to arterial stiffness, but rather adipocyte size. Here, subcutaneous 
adipocyte volume was the only metabolic or adipose variable that predicted improvements in 
PWV following significant weight loss. This is in line with a meta-analysis finding no 
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correlation between baseline weight and reductions in PWV following weight loss [118]. 
Many of the phenotypic changes seen in larger adipocytes that could potentially impact on 
PWV were outlined above. In addition, larger subcutaneous adipocytes may be indicative of 
an inability to further expand the subcutaneous adipose tissue depot, resulting in ectopic lipid 
deposition [163] which can occur along the arterial wall, potentially leading to arterial 
stiffening [112]. 
Interestingly, subcutaneous WAT COL4A1 expression was also independently linked to 
reductions in PWV following weight loss. This collagen alpha chain, which makes up 
basement membranes of blood vessels, has previously been linked to arterial stiffness in both 
genome wide association studies [164] and, in lymphoblastoid cell line gene expression 
[147]. Thus, it is unclear if this constitutes an adipose tissue specific or more general marker 
of arterial stiffness. There was no association between subcutaneous adipocyte size and 
COL4A1 expression indicating that they may affect or be related to arterial stiffness through 
different mechanisms. 
5.1.3 Study III 
While insulin resistance is known to influence BP, this was the first study to show increased 
insulin sensitivity in adipose tissue in obese who improved in blood pressure following 
weight loss. Skeletal muscle insulin resistance is a well-known feature of hypertension [165] 
and results suggest that insulin resistance needs to abate in all tissues or hypertension will 
remain despite weight loss.  
We also investigated (currently not in this version of the manuscript) the insulin induced 
WAT gene expression in a group of eight normotensive never obese controls (matched with 
the non-improved group for anthropometric measures including BMI and age, skeletal 
muscle -, and hepatic insulin sensitivity) and found them to have the highest number of 
regulated genes (n=358), further suggesting a relationship between WAT insulin resistance 
and blood pressure. 
As there were no differences in fasting gene expression, it is unlikely that the WAT 
phenotype differs regarding inflammation, hypoxia, or fibrosis. Likely the WAT in the 
improved group is more dynamic but burdened by obesity, and the effect of any anti-
hypertensive factors is suppressed but ameliorates with weight loss. Genes selectively 
regulated in both the improved and never obese groups includes several which have 
previously been linked to BP: ADAMST1 (beneficial vascular wall remodeling) [166], 
DUSP4 and HOXA9 (nitric oxide production) [167, 168], SESN2 (redox 
balancing/endothelial health) [169], and NOTCH1 and HES1 (arterial remodeling and 
homeostasis) [170, 171].  
5.1.4 Study IV 
This was the first study that investigated the lipolytic effect of ANP in obese humans. We 
found that, similar to catecholamine induced lipolysis, ANP stimulated lipolysis was blunted 
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but this was reversed after weight loss. Furthermore, an in situ microdialysis experiment with 
locally administered hANP also showed a blunted lipolytic response in overweight compared 
to lean men. Alterations in the signaling cascade with a lower WAT amount of receptor 
NPRA and a trend towards an increased amount of clearance receptor NPRC may explain the 
altered response. Our results, including changes in NPRA receptor expression have 
subsequently been corroborated in another study [172]. Recently it was also shown that 
catecholamine stimulated lipolysis in obesity is diminished due to a downregulation of its 
cell-surface receptor, in part due to pro-inflammatory factors like TNFα [173] 
Changes in lipolysis have systemic effects and a high basal and low catecholamine stimulated 
lipolysis associate with weight gain [174], while an increase in both basal and stimulated 
catecholamine lipolysis are linked to higher cardiovascular risk scores, but interestingly no 
such association is seen for ANP stimulated lipolysis [157]. Low levels of ANP correlate 
with increased risk of developing diabetes [175], and while we found associations between 
ANP lipolysis and various measures of insulin sensitivity these associations became non-
significant when adjusting for BMI. In summary, while ANP stimulated lipolysis is 
dysregulated in obesity, it is still unclear what specific pathological consequences this may 
incur.  
5.2 LIMITATIONS 
None of the study designs in this thesis can provide causality, as they are not randomized but 
observational by design.  
The NEFA cohort includes mainly women of Caucasian descent (personal observation, we 
did not collect data on ethnicity), limiting generalizability of our results with regards to men 
and other ethnicities. As we recruited the cohort from surgical clinics from individuals who 
voluntarily agreed to undergo bariatric surgery there were few men available for inclusion, as 
they less frequently opt for the procedure. We handled the low number of men differently in 
the studies: they were excluded in Study III and IV and included in Study I and II. In Study I 
there were some differences in visceral adipose characteristics between men and women, but 
we performed an analysis of covariance to control for the influence of gender, which was 
non-significant. Nevertheless, more studies with larger cohorts of men would be needed to 
confirm that associations between our variables and outcomes are true also for males. The 
same applies for being able to generalize our results to other ethnic groups. 
Our subjects lost weight by bariatric surgery. This method of weight loss may induce specific 
metabolic changes that may not be seen by diet and exercise achieved weight loss [176]. 
In Study I and II we use a brachial oscillometric method to measure PWV instead of the gold 
standard direct (through an intravascular catheter) or indirect (by use of mechanotransducers 
or tonometers placed directly on the carotid and femoral artery) technique to measure PWV. 
While cardiovascular outcome studies do not currently exist for the oscillometric method, 
methodological papers found good reproducibility and validity in comparison with direct 
[177] and gold standard carotid-femoral [178] measurements. Importantly we used the same 
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method for our follow-up two years later. We also took care to follow all expert 
recommendations for measuring PWV [107]. Furthermore, we also used a non-validated 
scale to capture self-reported exercise (included in Study II and III), it’s possible that a 
different, well established, questionnaire may have yielded other results. 
Depot specific differences affect adipose tissue phenotype [23]. In Study II and III we use 
gene expression to characterize the adipose tissue and correlate these findings to outcomes. 
Here it is important to note that we have only sequenced the subcutaneous adipose tissue 
depot and different adipose tissue depots may have varying and different gene expression. 
Depot differences also exist with regards to catecholamine stimulated lipolysis [179] and it 
would be of interest to perform the same investigations in Study IV in visceral adipose tissue 
to determine if similar differences exist in ANP stimulated lipolysis. 
Finally, Study III undertook a secondary analysis of the cohort, i.e., none of the pre-defined 
outcomes from the clinical trial. Had we recruited specifically for a BP study we likely would 




Specific WAT factors predict and correlate with important changes in the circulatory system, 
namely:  
• Visceral adipocyte volume is the only WAT factor that is independently associated 
with PWV (Study I). 
• Subcutaneous adipocyte volume and WAT COL4A1 expression predict 
improvements in PWV following significant weight loss (Study II). 
• Subcutaneous WAT insulin sensitivity is higher in subjects who improve in blood 
pressure following significant weight loss (Study III). 
and 
• ANP stimulated lipolysis is blunted in obesity, likely due to a downregulation in 





7 POINTS OF PERSPECTIVE 
This thesis provides a starting point for future research in several areas. 
Study II established that weight loss led to sustained reductions in PWV, however the cohort 
had just a slightly raised PWV. To further inform clinical decision making it would be 
interesting to perform two more trials. Firstly, to follow the current cohort with a matched 
obese group who did not undergo surgery and has a similar baseline PWV as the intervention 
group. We could then establish if weight loss protects against worsening PWV with 
increasing age. Secondly, to recruit an obese cohort with a high baseline PWV (>10-12 m/s) 
and measure the effect of significant weight reduction (by surgery, pharmacotherapy and/or 
lifestyle intervention). 
All sequencing in these studies was done in bulk, which cannot capture the potential 
heterogeneity of cell types in tissue. It is possible that a different make up or proportion of 
immune cells may have impacted on results. Mature white adipocytes have also been shown 
to display heterogeneity, with markedly different responses to insulin [180]. This 
heterogeneity could influence adipose tissue response to lipolysis, as well as potentially have 
systemic effects on blood pressure and arterial stiffness. Prospective weight change studies 
designed and recruited for these outcomes with detailed sequencing would be of interest, but 
expensive considering current methodology costs.  
Less expensive, but of interest, would be a study investigating the effect of adipose tissue 
insulin sensitivity and blood pressure. Sampling adipose tissue and subjecting ex vivo tissue 
pieces or isolated mature adipocytes to direct traditional insulin sensitivity experiments in 
hypertensive and normotensive obese cohorts, would in a cross-sectional setting shed further 
light on the association between adipose tissue insulin sensitivity and hypertension. This 
would ideally be combined with a hyperinsulinemic euglycemic clamp to assess skeletal 
muscle insulin sensitivity. Cohorts would then be followed after weight loss and any changes 
in circulatory outcomes, with a repeat of subject phenotyping.  
Furthermore, as mentioned previously, adipose tissue depot specific difference exists. 
Perivascular adipose tissue, with the ability to exert paracrine effects due to its proximity to 
vessels, has been shown to have a direct impact on the circulatory system [181, 182]. It would 
be of special interest to sample and phenotype this depot. Accessibility, sampling must be 
done during surgery, limits available study design, but cross-sectional studies would still be 
of interest, and potential results could be followed up and mechanistically investigated in 
animal models.  
Finally, a question which is adjacent to this thesis but nevertheless of interest, is if we should 
implement arterial stiffness measurements in clinical practice. It is an independent treatable 
risk factor for cardiovascular mortality that is currently never screened for in Swedish clinical 
practice. However, any health gains from implementing this method would have to be 
weighed against the cost of educating healthcare staff in the use and interpretation of different 
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devices, as well as establishing treatment guidelines and follow-up procedures. Currently at 
least 25% of individuals with hypertension, an even stronger risk factor for cardiovascular 
mortality and morbidity, remain undiagnosed in Sweden, indicating that the time may not be 
right for implementing another vascular measurement. A middle of the road option would be 
for clinicians to use pulse pressure, which is readily available with just a normal BP 
measurement. Measuring arterial stiffness by PWV has a greater prediction value compared 
to PP [183], however PP still has been found to be a predictor of CVD even in normotensive 
subjects [184] and a stronger predictor of CVD death compared to systolic BP in 
hypertensive cohorts [185-187]. Identifying populations with increased arterial stiffness may 
help inform treatment choice both with lifestyle interventions as well as potentially 
pharmacotherapy choices, as clinical trials have shown differential effect on arterial stiffness 
despite similar reductions in BP [188, 189], however first line drug choice for hypertension 
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